Discovery of a novel natural compound, vitekwangin B, with ANO1 protein reduction properties and anticancer potential

Yohan Seo1, Sion Lee1, Minuk Kim2

  • 1New Drug Development Center, Daegu Gyeongbuk Medical Innovation Foundation (KMEDIhub), Daegu, Republic of Korea.

PubMed

Insights

Vitekwangin B, a natural compound, effectively inhibits prostate cancer and non-small cell lung cancer (NSCLC) cell growth by reducing ANO1 protein levels. This compound shows promise as a novel anticancer therapeutic with minimal toxicity.

Area of Science:

  • Natural Product Chemistry
  • Oncology
  • Pharmacology

Background:

  • Prostate cancer and non-small cell lung cancer (NSCLC) pose significant therapeutic challenges.
  • Current treatments for prostate cancer and NSCLC face limitations, including drug resistance.
  • Prostatic small-cell neuroendocrine carcinoma has limited treatment options.

Purpose of the Study:

  • To investigate the anticancer properties of vitekwangin B, a compound isolated from *Vitex trifolia*.
  • To explore vitekwangin B as a novel therapeutic agent for prostate cancer and NSCLC.
  • To evaluate the effect of vitekwangin B on anoctamin1 (ANO1) protein levels and cancer cell viability.

Main Methods:

  • Vitekwangin B was isolated from *Vitex trifolia* fruits using chromatography.
  • ANO1 protein levels were assessed in prostate cancer and NSCLC cells before and after vitekwangin B treatment.
  • Cancer cell viability and apoptosis were evaluated, along with toxicity to liver cells and hERG channel activity.

Main Results:

  • Vitekwangin B significantly reduced ANO1 protein levels in cancer cells.
  • Vitekwangin B demonstrated potent inhibition of cancer cell viability and induced apoptosis.
  • The compound exhibited minimal toxicity to liver cells and did not affect hERG channel activity.

Conclusions:

  • Vitekwangin B shows potential as a novel anticancer drug targeting ANO1 protein.
  • This natural compound may offer a new therapeutic strategy for prostate cancer and NSCLC.
  • Further research is warranted to fully elucidate vitekwangin B's potential and overcome drug resistance.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.8K